



LKT Laboratories, Inc.

Crizotinib

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID C6935

CAS No. 877399-52-5

Chemical Name 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine

Synonym Xalkori

Formula C₂₁H₂₂Cl₂FN₅O

Formula Wt. 450.34

Melting Point


Purity ≥98%

Solubility

Store Temp Ambient

Ship Temp Ambient

Description Crizotinib is an inhibitor of anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and c-MET, binding competitively to the ATP-binding pocket of kinases. Crizotinib exhibits anticancer chemotherapeutic benefit in the treatment of non-small cell lung cancer (NSCLC) and is currently in clinical trials as a potential treatment for neuroblastoma and other advanced solid tumors. In cellular models, this compound upregulates expression of pro-apoptotic BIM and downregulates expression of anti-apoptotic survivin to induce apoptosis and inhibit cell proliferation.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
C6935	5 mg	\$102.00
C6935	10 mg	\$153.10
C6935	25 mg	\$337.10
C6935	100 mg	\$816.70

References Timm A, Kolesar JM. Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7. PMID: 23686600.

Okamoto W, Okamoto I, Arao T, et al. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. PMID: 22729845.

Tanizaki J, Okamoto I, Okamoto K, et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol. 2011 Oct;6(10):1624-31. PMID: 21716144.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.